Renovaro to Acquire Predictive Oncology in All-Stock Transaction

 Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data

Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul

Combines Predictive Oncology’s AI-driven multi-omic drug discovery platform with Renovaro’s AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug discovery

Planned test launch to assist physicians in individualizing cancer therapy to improve treatment outcomes\

https://www.globenewswire.com/news-release/2025/01/06/3004710/0/en/Renovaro-to-Acquire-Predictive-Oncology-in-All-Stock-Transaction.html